Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells
article
OA: bronze
CC0
⤵ 12 in-corpus citations
AI-generated summary
Epigallocatechin gallate demonstrated antiproliferative and proapoptotic effects on human leiomyoma cells in this study.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectiveTo investigate the effects of epigallocatechin gallate (EGCG), an extract of green tea on cultured human leiomyoma cells (HuLM).DesignLaboratory study.SettingUniversity hospitals.Patient(s)Not applicable.Intervention(s)Not applicable.Main outcome measure(s)The HuLM cells were treated with various EGCG concentrations. Cell proliferation was assayed using Hoechst 33258 dye, and apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Total RNA was isolated, and gene expression profiling was performed on 84 key genes related to 18 different signal transduction pathways. The protein levels of PCNA, CDK4, BCL2, and BAX were examined by Western blot analysis.Result(s)The HuLM cells treated with EGCG showed a dose-dependent and time-dependent inhibition of cell proliferation. The TUNEL staining indicated a significant increase in apoptosis in HuLM cells treated with 100 μM of EGCG compared with untreated control. Gene expression profiling indicated that EGCG treatment up-regulated representative genes from the transforming growth factor β (TGF-β) and stress pathways, while inhibiting the survival pathway and NFκB-dependent inflammatory pathway. Western blot analysis confirmed that EGCG at ≥50 μM significantly decreased the expression of PCNA, CDK4, and BCL2 as well as increased the expression of the proapoptotic BAX in a dose-dependent manner.Conclusion(s)Epigallocatechin gallate inhibits the proliferation of HuLM cells and induces apoptosis. These results suggest that EGCG may be a potential anti-uterine fibroid agent acting through multiple signal transduction pathways.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (43)
- doi:10.1152/ajpgi.00482.2005 via openalex
- doi:10.1074/jbc.275.9.6421 via openalex
- doi:10.1093/toxsci/52.suppl_1.111 via openalex
- doi:10.1016/j.jsgi.2006.09.003 via openalex
- doi:10.1016/s0304-3835(98)00108-6 via openalex
- doi:10.1007/bf02975249 via openalex
- doi:10.1016/j.cancergencyto.2006.05.003 via openalex
- doi:10.1016/s0140-6736(00)03622-9 via openalex
- doi:10.1006/abbi.2000.1742 via openalex
- W1907000598 via openalex
- doi:10.1016/s0006-2952(99)00112-4 via openalex
- doi:10.1016/j.bpobgyn.2008.04.002 via openalex
- doi:10.1016/j.cellsig.2007.01.017 via openalex
- doi:10.2174/187152006778226468 via openalex
- doi:10.1038/sj.onc.1210834 via openalex
- doi:10.1097/01.lab.0000017499.51216.3e via openalex
- W2125565767 via openalex
- W2167417479 via openalex
- W2628053793 via openalex
- W6639860694 via openalex
- W6647934444 via openalex
- W6678613437 via openalex
- doi:10.1002/mc.20158 via openalex
- doi:10.1093/ajcp/94.4.435 via openalex
- doi:10.1124/dmd.31.5.572 via openalex
- doi:10.1159/000095627 via openalex
- doi:10.1093/jnci/89.24.1881 via openalex
- doi:10.1021/bm0342436 via openalex
- doi:10.1016/j.bpobgyn.2008.01.014 via openalex
- doi:10.1002/pros.10361 via openalex
- doi:10.1158/1078-0432.ccr-03-0672 via openalex
- doi:10.1006/bbrc.2000.3297 via openalex
- doi:10.1083/jcb.124.1.1 via openalex
- doi:10.1002/mnfr.200600173 via openalex
- doi:10.1097/00006254-198701000-00001 via openalex
- doi:10.1038/sj.cdd.4400918 via openalex
- doi:10.1016/j.jsgi.2005.10.007 via openalex
- doi:10.1016/s0027-5107(97)00150-4 via openalex
- doi:10.1002/(sici)1097-4652(200006)183:3<425::aid-jcp16>3.0.co;2-m via openalex
- doi:10.1093/humrep/del353 via openalex
- doi:10.1016/s0029-7844(97)00534-6 via openalex
- doi:10.3892/ijo.31.4.705 via openalex
- doi:10.1006/taap.1999.8885 via openalex
Cited by (11)
- The Potential of Vitamin D and Epigallocatechin Gallate (EGCG) for the Treatment of Uterine Fibroids: Evidence From In Vitro to Clinical Studies 2025
- Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids 2024
- Serum Oxidative Stress Markers in Women with Uterine Fibroids in Lagos, Nigeria 2021
- Herbal Medicine in Uterine Fibroid 2020
- Benign Uterine Diseases 2019
- Novel Drug Targets with Traditional Herbal Medicines for Overcoming Endometriosis 2018
- ACTIVELY WORKING SUBSTANCE FROM THE GREEN TEA FOR THE TREATMENT OF ENDOMETRIOSIS AND UTERINE FIBROIDS. VIEW ON THE PROBLEM OF GERMAN AND RUSSIAN EXPERTS 2017
- Antiangiogenic Agents in Natural Products for the Treatment of Gynecologic Disorders 2014
- Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: Promising options for prevention and treatment of uterine fibroids? 2014
- Natural therapies assessment for the treatment of endometriosis 2012
- Innovative Oral Treatments of Uterine Leiomyoma 2012
Source provenance
- openalex
- last seen: 2026-05-11T06:17:40.080092+00:00
License: CC0
· commercial use OK